Clinical trials
ATTR-CM clinical trials
Below are recruiting attr-cm clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06465810Recruiting
Observational study for ATTR amyloidosis patients
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
La Jolla, CaliforniaAges 18–130 - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT04935021RecruitingPhase 4
Study of ATTR cardiac amyloidosis in patients and gene carriers
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
Hangzhou, ZhejiangAges 18–80 - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Tucson, ArizonaAges 18–90 - NCT06338696Recruiting
Thailand ATTR-CM patient registry
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
BangkokAges 18–100 - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT07235462Recruiting
Acoramidis for heart disease due to TTR amyloidosis
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
HeidelbergAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Scottsdale, ArizonaAges 18 years+ - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT07690436Recruiting
Eye imaging for detecting a type of heart disease
This study uses retinal imaging (pictures of the back of the eye) and OCT scans to look for signs of a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It may help doctors find this condition with an eye exam instead of more invasive tests.
Palo Alto, CaliforniaAges 18 years+ - NCT07306949RecruitingPhase 4
Acoramidis for transthyretin cardiac amyloidosis
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
Bunkyō CityAges 18–100 - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT05776212Recruiting
Imaging study for certain heart amyloidosis types and heart thickening
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
GroningenAges 40 years+ - NCT07112066Recruiting
Heart imaging study for ATTR amyloidosis patients
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Zurich, Canton of ZurichAges Any age - NCT07196839Recruiting
Study of heart medication and amyloid levels over time
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Dallas, TexasAges 30–80 - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Naples, FloridaAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+
Hear when a new ATTR-CM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for attr-cm?
- Yes. Clin2 currently lists 18 recruiting attr-cm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a attr-cm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a attr-cm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.